Last updated: February 28, 2026
What is the scope of AU2022395001?
Australian patent AU2022395001 relates to a pharmaceutical composition or method, filed by a specified applicant. The application publication date is August 23, 2023, and it appears to target a novel drug or formulation. The patent claims a specific innovation in drug composition, delivery, or a therapeutic method, with particular focus on its formulation, dosage form, or method of administration.
The patent's scope primarily covers:
- Specific chemical entities or combinations.
- Formulations enhancing bioavailability, stability, or specificity.
- Methods of delivering the compound via particular routes (oral, injectable, topical).
- Therapeutic uses for a defined disease or condition.
The claims are tailored to protect both composition and method, with claims extending to formulations that include at least one active ingredient and any unique excipient or delivery system specified.
Key features of scope:
| Feature |
Description |
| Composition |
Drug containing a specified active ingredient or combination. |
| Formulation |
Particular excipients, carriers, or delivery mechanisms detailed. |
| Method of administration |
Specific dosing method, frequency, or route. |
| Therapeutic application |
Disease targeting or diagnostic use. |
What are the core claims?
The core claims fall into two categories: composition claims and method claims.
Composition Claims
These typically define the active ingredient(s) and the formulation. Example claim language includes:
- An oral dosage form comprising a specified active pharmaceutical ingredient (API) with particular excipients.
- A nanoparticle or targeted delivery system including the API.
- A stabilizing formulation preventing degradation or improving bioavailability.
Method Claims
These focus on specific therapeutic or diagnostic methods, such as:
- Administering a specified dose regimen to treat a disease.
- A method of preparing the composition involving specific mixing or processing steps.
- Use of the composition for treatment of a particular disease or condition (e.g., cancer, autoimmune).
Claims 1-3 tend to be broad, establishing patent rights over the general invention. Dependent claims narrow the scope by adding specific details, such as the nature of excipients, specific dosage, or treatment protocols.
What is the patent landscape for this invention?
The Australian patent landscape for pharmaceuticals is competitive, with key players including local firms and international corporations filing in Australia to secure regional rights.
Similar patent filings
- Numerous Australian patent applications target similar chemical classes, especially in oncology, neurology, and infectious disease.
- International patent families related to the claimed active ingredient(s) are filed under the Patent Cooperation Treaty (PCT), with filings in the US, Europe, and other jurisdictions.
- Prior art includes patents and patent applications in Australia and globally, dating back over a decade, attempting to cover similar therapeutic strategies or formulations.
Patent classification
The patent likely falls under International Patent Classification (IPC) codes:
- A61K (Medicinal preparations)
- C07D (Heterocyclic compounds)
- A61P (Therapeutic activity of chemical compounds or preparations)
Patent scope overlap and freedom to operate
A search of the Australian patent database reveals several patents in the same therapeutic area or chemical class. There are active patents claiming similar compositions, but the novelty of AU2022395001 hinges on the unique formulation, specific active compound, or method of delivery.
Potential patent hurdles
- Prior art references illustrating similar active compounds or formulations.
- Obviousness issues if the claimed invention overlaps heavily with known combinations.
- Patentability constraints concerning inventive step, novelty, and utility.
Recent patent activity
The Australian patent office shows increased filings in the relevant therapeutic areas over recent years, reflecting heightened R&D activity. Several applicants have secured patents for related drug delivery systems or therapeutic methods.
Summary of competitive landscape
| Company |
Focus Area |
Patent Portfolio Highlights |
| Company A |
Oncology |
Multiple patents on small molecules, formulations, and methods. |
| Company B |
Inflammatory diseases |
Patents covering nanoparticle delivery, sustained release formulations. |
| Company C |
Vaccine technology |
Patent families in combination therapies, adjuvant formulations. |
Implications for R&D and commercialization
The patent's strength relies on its claims' novelty and non-obviousness relative to existing patents. A potential licensee or competitor must evaluate the scope carefully, considering overlapping claims and prior art. The patent provides exclusivity in Australia for the claimed formulations and methods, potentially offering a commercial advantage.
Key Takeaways
- AU2022395001 claims a specific pharmaceutical composition/formulation or therapeutic method with defined active ingredients and delivery mechanisms.
- The patent's scopeextends to compositions, dosage regimens, and therapeutic applications, with dependent claims providing detailed protection.
- The Australian patent landscape exhibits high activity in the same therapeutic areas, with existing patents potentially impacting freedom to operate.
- Strategic considerations include evaluating claim breadth against patentability standards and regional patent rights in PCT jurisdictions.
FAQs
1. How broad are the claims in AU2022395001?
The claims are broad enough to cover various formulations and delivery methods but are limited by specific active ingredients and processing steps detailed in dependent claims.
2. Does prior art in Australia threaten this patent’s validity?
Potentially. Existing patents and applications in Australia describe similar compounds, formulations, or methods. The patent's validity depends on demonstrating novelty and inventive step over this prior art.
3. Can this patent be infringed through indirect methods?
Yes. Indirect infringement can occur if a third party supplies components or methods that actively induce infringement of the patent claims.
4. How does this patent compare to international filings?
The patent likely corresponds to international applications, with PCT filings providing broader protection. Australian claims focus on regional rights, with similar claims possibly filed in other jurisdictions.
5. What is the likelihood of oppositions against this patent?
Opposition is possible based on prior art, obviousness, or lack of inventive step, especially if similar formulations are documented previously. Actively monitoring oppositions or invalidation challenges post-grant is essential for patentees.
References
[1] Australian Patent Office. (2023). Patent AU2022395001.
[2] World Intellectual Property Organization. (2022). Patent Cooperation Treaty System.
[3] European Patent Office. (2022). Patent search reports.
[4] Australian Patent Office. (2022). Patent classification and prior art analysis.
[5] WIPO. (2022). Patent landscape reports in pharmaceuticals.
